Science of Immunology and Cancer

Cancer treatment has entered a remarkable new era over the past decade. Advances in immunotherapy have transformed outcomes for many patients, allowing the body’s own immune system to identify and attack cancer cells. However, despite these breakthroughs, immunotherapy does not work for everyone.

For many patients, tumours eventually develop ways to hide from the immune system, allowing the cancer to continue growing despite treatment. This has remained one of the biggest challenges facing cancer researchers worldwide.

Now, scientists have reported encouraging early results from a new experimental drug known as GRWD5769. The treatment has attracted international attention after clinical trial data suggested that it may help immunotherapy work again in patients whose cancers had previously stopped responding to treatment.

The findings were presented at the annual meeting of the American Society of Clinical Oncology (ASCO), one of the world’s most important cancer conferences.

While still at an early stage of development, the results have generated optimism among cancer specialists because the treatment appears to work across several different cancer types, including some cancers that are traditionally difficult to treat.

What Is GRWD5769?

GRWD5769 is a new type of cancer treatment developed to help the immune system recognise and attack cancer cells more effectively.

Unlike chemotherapy, which directly attacks rapidly dividing cells, or traditional immunotherapy, which stimulates the immune system, GRWD5769 targets a specific mechanism that some cancers use to avoid detection.

Cancer cells are constantly evolving. One of their survival mechanisms involves hiding from the body’s immune defences. When this happens, even powerful immunotherapy drugs can become ineffective because the immune system simply cannot see the cancer.

Researchers believe GRWD5769 may overcome this problem.

The drug targets an enzyme called ERAP1. This enzyme plays a role in how proteins are displayed on the surface of cancer cells. By blocking ERAP1, scientists hope to expose hidden cancer markers and make tumours visible once again to immune cells.

In simple terms, the treatment attempts to remove part of the cancer’s disguise.

Once the tumour becomes visible again, the immune system can potentially identify and attack it.

How Does The Treatment Work?

The treatment combines GRWD5769 with an existing immunotherapy drug called cemiplimab.

Patients take GRWD5769 as an oral tablet.

The treatment is given in cycles:

• Three weeks taking the drug
• Three weeks off treatment
• Regular immunotherapy infusions alongside the tablet treatment

Researchers believe the treatment breaks help immune cells recover before launching another attack against the cancer.

The aim is not simply to stimulate the immune system but to repeatedly refresh and strengthen its ability to recognise cancer cells.

Which Cancers Were Included In The Trial?

The study involved patients with several advanced cancers that had either failed to respond to treatment or had stopped responding after an initial benefit.

The cancers included:

• Cervical cancer
• Bladder cancer
• Liver cancer
• Non small cell lung cancer
• Head and neck squamous cell carcinoma
• Certain forms of bowel cancer

Many of the patients involved had exhausted standard treatment options and had limited alternatives available.

This makes the findings particularly significant.

What Were The Results?

The early phase trial involved 83 patients across 28 cancer centres in four countries.

Researchers reported that:

• Tumours shrank in 26 patients
• Tumours shrank by at least 30 per cent in 15 patients
• Some patients experienced disease control lasting six months or more
• Side effects were reported to be relatively limited

One particularly encouraging finding involved bowel cancer.

Some bowel cancers are considered largely resistant to immunotherapy. However, researchers found that 51 per cent of these patients experienced disease stability for at least six months.

Among other cancer types:

• 36 per cent of bladder cancer patients achieved disease control
• 55 per cent of non small cell lung cancer patients achieved disease control
• 38 per cent of head and neck cancer patients achieved disease control
• 32 per cent of liver cancer patients achieved disease control
• 18 per cent of cervical cancer patients achieved disease control

While these results do not represent a cure, they provide an important indication that the treatment may be helping the immune system regain control over cancers that had become resistant to existing therapies.

The Christie’s Role In The Research

A key part of the research was conducted at The Christie NHS Foundation Trust in Manchester.

The Christie is internationally recognised for cancer treatment and research and is one of Europe’s leading specialist cancer centres.

The hospital has played a major role in the development of many cancer treatments and clinical trials over recent decades.

Its extensive Research and Innovation Programme allows patients to access cutting edge treatments years before they become widely available.

Professor Fiona Thistlethwaite, Consultant Medical Oncologist and Medical Director of the Clinical Research Facility at The Christie, described the findings as particularly encouraging.

Her specialist profile can be viewed on The Christie’s Consultant Directory.

Professor Thistlethwaite noted that it is unusual to see both strong efficacy signals and low toxicity so early in a drug’s development.

Although she stressed that further research remains necessary, she stated that the results provide genuine optimism for the future.

Why Immunotherapy Does Not Work For Everyone

Immunotherapy has transformed cancer treatment.

For some patients, it has delivered survival outcomes that would have seemed impossible only a generation ago.

However, immunotherapy remains ineffective for many patients.

Current estimates suggest that only around one third of cancer patients derive substantial long term benefit from immunotherapy.

There are several reasons for this:

• Tumours may lack recognisable targets
• The immune system may be suppressed
• Cancer cells may evolve to evade detection
• Certain tumour environments may prevent immune attack

The development of treatments such as GRWD5769 is designed to address one of these major barriers by making cancer cells visible once again.

Why Early Cancer Diagnosis Remains Critical

Exciting new treatments often generate headlines, but they do not remove the importance of early diagnosis.

For most cancers, earlier diagnosis remains one of the most important factors influencing outcome.

Early diagnosis may:

• Increase treatment options
• Improve survival rates
• Reduce the need for aggressive treatment
• Improve quality of life
• Reduce complications

Unfortunately, delayed diagnosis continues to occur throughout the UK healthcare system.

Patients sometimes experience delays because:

• Symptoms are not recognised
• Referrals are delayed
• Test results are overlooked
• Investigations are not arranged promptly
• Follow up appointments are delayed

In some cases, earlier diagnosis may have significantly altered the patient’s treatment options or prognosis.

Can You Claim Compensation For A Delayed Cancer Diagnosis?

Not every delayed diagnosis amounts to medical negligence.

However, where a healthcare provider has failed to provide treatment that met a reasonable standard of care, a compensation claim may be possible.

Examples can include:

• Failure to investigate symptoms properly
• Delayed referral to specialists
• Failure to arrange scans or biopsies
• Misinterpretation of imaging
• Failure to act on abnormal test results
• Delayed treatment after diagnosis

A successful claim may compensate for:

• Pain and suffering
• Loss of treatment opportunities
• Reduced life expectancy
• Financial losses
• Care and assistance needs
• Family dependency claims in fatal cases

Speak To A Specialist Delayed Cancer Diagnosis Solicitor

At Hutcheon Law, we understand the devastating impact that delayed cancer diagnosis can have on patients and families.

Whether the delay involved cancer symptoms being overlooked, investigations not being carried out promptly, or test results not being acted upon appropriately, specialist legal advice can help establish whether a claim may be available.

For further information about bringing a claim, visit our delayed cancer diagnosis claims page.

As research continues into promising treatments such as GRWD5769, the medical community hopes more patients will benefit from innovative therapies. However, ensuring that cancer is diagnosed promptly remains just as important as developing new treatments. When delays occur unnecessarily, patients and families deserve answers.